List of Excipients in Branded Drug SYNAREL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	SYNAREL	nafarelin acetate	0025-0166	ACETIC ACID
Pfizer Laboratories Div Pfizer Inc	SYNAREL	nafarelin acetate	0025-0166	BENZALKONIUM CHLORIDE
Pfizer Laboratories Div Pfizer Inc	SYNAREL	nafarelin acetate	0025-0166	HYDROCHLORIC ACID
Pfizer Laboratories Div Pfizer Inc	SYNAREL	nafarelin acetate	0025-0166	SODIUM HYDROXIDE
Pfizer Laboratories Div Pfizer Inc	SYNAREL	nafarelin acetate	0025-0166	SORBITOL
Pfizer Laboratories Div Pfizer Inc	SYNAREL	nafarelin acetate	0025-0166	WATER

Synarel Excipient Strategy and Commercial Opportunities in Nafarelin Nasal Spray

Last updated: August 25, 2026

Synarel is a prescription intranasal formulation of nafarelin acetate, a gonadotropin-releasing hormone agonist used for endometriosis and central precocious puberty. Its commercial formulation uses a relatively simple aqueous vehicle containing benzalkonium chloride, citric acid, sodium chloride, and purified water. The strongest product-development opportunities are not new active-ingredient claims. They are preservative-free delivery, improved nasal tolerability, dose-consistent device performance, pediatric usability, and differentiated lifecycle management.

What is Synarel and which excipients does it contain?

Synarel contains nafarelin acetate at 2 mg/mL. Each metered spray delivers approximately 200 mcg of nafarelin. The product is supplied as a multidose nasal spray and is administered intranasally, generally twice daily depending on indication and treatment stage. The FDA labeling identifies the inactive ingredients as benzalkonium chloride, citric acid, purified water, and sodium chloride.[1]

Product attribute	Synarel profile
Active ingredient	Nafarelin acetate
Therapeutic class	GnRH agonist
Dosage form	Multidose nasal solution
Strength	2 mg/mL
Delivered dose	Approximately 200 mcg per spray
Key indications	Endometriosis; central precocious puberty
Preservative	Benzalkonium chloride
Buffering agent	Citric acid
Tonicity agent	Sodium chloride
Vehicle	Purified water
Administration	Intranasal
Primary formulation risk	Chronic nasal exposure to preservative and local tolerability issues

The formulation is a solution rather than a suspension. That reduces particle-size and redispersibility issues but increases the importance of chemical stability, pH control, preservative effectiveness, pump compatibility, and delivered-volume consistency.

How does Synarel’s excipient system work?

Benzalkonium chloride provides multidose microbial protection

Benzalkonium chloride is used as a preservative in multidose aqueous nasal products. It limits microbial growth after repeated actuation and handling. Its commercial value is operational: it allows a multidose bottle rather than a single-use presentation.

The principal development concern is chronic nasal exposure. Published literature has associated repeated exposure to benzalkonium chloride with local mucosal irritation and, in some settings, impaired mucociliary function.[2,3] The relevance depends on concentration, exposure frequency, treatment duration, patient population, and the total formulation environment.

For Synarel, the preservative is a clear target for lifecycle improvement because:

• Endometriosis treatment can involve prolonged administration.
• Pediatric patients may receive treatment over extended periods.
• Nasal irritation can reduce adherence.
• A preservative-free presentation could differentiate the product without changing the active ingredient.
• A new container-closure system could support a reformulation strategy.

A preservative-free multidose format would require a validated antimicrobial barrier, such as a mechanically protected pump, sterile manufacturing process, unit-dose container, or another approved multidose technology. Removing benzalkonium chloride without redesigning the package would create a microbiological risk.

Citric acid controls the formulation environment

Citric acid acts primarily as an acidifying and buffering component. Nafarelin stability depends on control of pH, ionic environment, temperature, light exposure, and contact with container materials. The buffer system also affects nasal sensation and tissue tolerability.

A reformulation program should screen:

• Citric acid concentration.
• Final pH range.
• Buffer capacity.
• Osmolality.
• Chemical degradation products.
• Adsorption or absorption to pump and container materials.
• Compatibility with preservatives or preservative-free packaging.

A lower buffer capacity may improve tolerability but could reduce resistance to pH drift during storage. A stronger buffer may improve stability while increasing nasal discomfort. The optimal formulation is therefore a balance between chemical robustness and local tolerability.

Sodium chloride adjusts tonicity

Sodium chloride is used to adjust tonicity. A near-isotonic nasal solution can reduce stinging and discomfort compared with a markedly hypertonic or hypotonic solution. Tonicity also affects evaporation, spray plume behavior, and patient perception.

The commercial opportunity is not sodium chloride itself. It is the broader formulation space around osmolality, pH, viscosity, and spray performance. Small changes can affect:

• Droplet-size distribution.
• Nasal deposition.
• Runoff into the throat.
• Perceived taste.
• Delivered dose.
• Local irritation.
• Pump actuation force.

What formulation patents could protect a new Synarel product?

The core nafarelin composition is an older product concept, so the most commercially relevant patent opportunities are likely to involve formulation and delivery claims rather than basic active-ingredient claims.

Potential claim categories include:

Claim area	Potential protection
Preservative-free formulation	Nafarelin aqueous solution without benzalkonium chloride
pH and buffer	Defined citric acid concentration or pH range linked to stability
Tonicity	Specific osmolality range linked to tolerability or spray performance
Device integration	Pump and container system that maintains sterility without a conventional preservative
Dose delivery	Metered pump delivering a defined nafarelin mass over bottle life
Local tolerability	Formulation with reduced irritation or improved mucociliary compatibility
Stability	Long-term stability under specified storage conditions
Pediatric usability	Device geometry, actuation force, dose counter, or administration aid
Manufacturing	Low-shear filling, sterile filtration, or container-closure controls
Combination of features	Nafarelin, defined pH, osmolality, preservative status, and spray characteristics

A defensible patent should connect the excipient selection to an unexpected technical effect. A claim directed only to replacing benzalkonium chloride may face obviousness challenges if the substitute is already conventional in nasal formulations. Stronger protection would tie the formulation to measured improvements in stability, preservative-free microbiological control, tolerability, dose uniformity, or clinical adherence.

When does Synarel lose exclusivity?

Synarel’s active pharmaceutical ingredient and original product concept have been commercially established for decades. The principal exclusivity risk is therefore generic or reformulated competition, not biosimilar competition.

Exclusivity category	Synarel assessment
Active-ingredient patent	Original compound and early product protection are historical
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the primary commercial framework for the labeled indications
Biologic exclusivity	Not applicable
Formulation exclusivity	Depends on later patents, if any, and current Orange Book listings
Method-of-use protection	Could remain relevant only if active and listed or otherwise enforceable
Regulatory exclusivity	Any historical exclusivity periods have elapsed
Generic pathway	Potentially ANDA or 505(b)(2), depending on product differences
Main current barrier	Nasal bioequivalence, device equivalence, manufacturing, and market size

A precise current patent-expiration analysis requires the live FDA Orange Book and Drugs@FDA records because listed patents, delistings, pediatric extensions, and marketing-status data can change. A historical product with no meaningful active patent barrier can still retain commercial protection through manufacturing complexity, limited demand, physician familiarity, and the cost of demonstrating nasal equivalence.

What is the Orange Book and FDA regulatory status of Synarel?

Synarel is an FDA-approved small-molecule drug product, not a biologic. The relevant regulatory pathways are an abbreviated new drug application under section 505(j) or a section 505(b)(2) application for a materially different formulation, device, or clinical approach.[4]

ANDA strategy

An ANDA applicant would generally seek to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. For an intranasal product, the program may require more than conventional plasma pharmacokinetics. FDA nasal-spray guidance emphasizes assessment of device performance, spray characteristics, drug distribution, and, where appropriate, pharmacokinetic or clinical data.[5]

Key ANDA workstreams include:

• Same active ingredient and strength.
• Comparable dosage form and route.
• Delivered-dose uniformity.
• Spray-pattern and plume-characterization testing.
• Droplet-size distribution.
• Priming and repriming performance.
• Container-closure integrity.
• Preservative effectiveness.
• Comparative stability.
• Human factors and device-use assessment.

A formulation that removes benzalkonium chloride, changes the pump, or materially changes pH would create greater 505(b)(2) risk than a close generic copy.

505(b)(2) strategy

A 505(b)(2) application could support:

• Preservative-free multidose delivery.
• A unit-dose nasal presentation.
• A new device with improved dose counting.
• Reduced local irritation.
• A different concentration or dosing schedule.
• A pediatric administration system.
• A new indication supported by clinical data.

The commercial advantage is differentiated labeling and potentially broader intellectual-property protection. The disadvantage is a larger clinical and regulatory package than a conventional ANDA.

What Paragraph IV challenges could affect Synarel?

A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed.[6] The commercial effect depends on whether Synarel has active listed patents and whether an applicant files an ANDA with a Paragraph IV certification.

Potential litigation triggers include:

• A listed formulation patent covering the nasal solution.
• A device or container-closure patent.
• A method-of-use patent covering endometriosis or central precocious puberty.
• A patent covering a dosing regimen.
• A patent covering a preservative system or stability profile.

If no relevant active patent is listed, an ANDA applicant could avoid a Paragraph IV dispute and pursue approval through other certifications. If a listed patent exists, a timely Paragraph IV notice could trigger a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and litigation outcomes.[6]

Because Synarel is an intranasal solution, litigation risk may focus less on the molecule and more on whether the proposed generic uses the same device, preservative system, pH, and metered-dose characteristics.

What commercial opportunities exist in Synarel excipient reformulation?

Preservative-free multidose nasal spray

This is the clearest formulation opportunity. A preservative-free product could reduce concerns about chronic benzalkonium chloride exposure and support premium positioning. The technology would need to prevent microbial ingress throughout the in-use period.

Commercial models include:

• A higher-priced branded reformulation.
• A line extension before generic entry.
• Licensing of a preservative-free nasal pump.
• A 505(b)(2) product with improved tolerability claims.
• A pediatric-focused product with simpler administration.

Unit-dose or short-duration packaging

Unit-dose packaging removes the need for a conventional preservative and can simplify microbiological control. Its disadvantages are higher packaging cost, greater waste, more frequent handling, and potentially lower convenience for twice-daily use.

The best fit may be pediatric therapy, institutional use, or patients with documented sensitivity to preservatives.

Alternative preservative systems

A substitute preservative could preserve multidose economics while avoiding benzalkonium chloride. Candidates must be evaluated for nasal safety, antimicrobial spectrum, compatibility with nafarelin, pump materials, and regulatory precedent. A substitute is commercially attractive only if it produces a measurable benefit without creating new irritation or stability problems.

Improved patient-use technology

Synarel requires consistent intranasal administration. A dose counter, improved actuation force, orientation control, or administration aid could reduce underdosing and misuse. Device claims may be stronger than broad excipient claims if the design generates reproducible dose delivery and usability data.

Pediatric formulation and packaging

Central precocious puberty is a pediatric indication. Commercial differentiation could focus on:

• Low-force actuation.
• Child-resistant but caregiver-friendly packaging.
• Dose-counting features.
• Administration instructions supported by human-factors testing.
• Reduced throat runoff and taste.
• More robust performance when the bottle is not held vertically.

A pediatric-oriented package may support a distinct brand strategy even if the formulation remains close to Synarel.

How strong is the Synarel patent estate?

The original composition-of-matter estate is commercially weak because nafarelin has been marketed for many years. The potential strength of a current product estate depends on later patents covering formulation, device, manufacturing, or method of use.

Estate component	Relative strategic value
Nafarelin molecule	Low for new exclusivity
Original nasal solution	Low to moderate, depending on surviving claims
Benzalkonium-containing formulation	Limited differentiation unless tied to a narrow technical result
Preservative-free formulation	Moderate to high if supported by stability and microbiological data
Device and dose-control claims	Moderate to high
Pediatric usability claims	Moderate, usually dependent on device implementation
Manufacturing process	Moderate if difficult to design around
Method-of-use claims	Variable; often vulnerable to label carve-outs
Trade secrets	Potentially meaningful for filling, sterilization, and device assembly

The strongest strategy is a layered estate combining formulation, device, packaging, stability, and manufacturing claims. A single broad claim to a nafarelin nasal solution would be easier to challenge and design around.

Which companies could challenge or compete with Synarel?

Competition can come from three sources:

1. Generic manufacturers developing nafarelin nasal spray.
2. Sponsors using 505(b)(2) to commercialize a new nasal presentation.
3. Alternative GnRH therapies that avoid intranasal administration.

Relevant competing modalities include injectable GnRH agonists, long-acting depot products, oral GnRH antagonists, and other treatments for endometriosis or central precocious puberty. These products compete on adherence, administration frequency, adverse-effect profile, reimbursement, and physician familiarity.

Nafarelin’s intranasal route creates a distinct vulnerability: patients must administer the product correctly and consistently. Long-acting injectable or implantable products can capture patients for whom twice-daily nasal dosing is impractical.

What manufacturing and IP barriers affect a Synarel competitor?

The active ingredient is not the main barrier. The higher-risk manufacturing elements are:

• Sterile or controlled microbiological filling.
• Consistent low-volume metered spraying.
• Pump and container compatibility.
• Dose uniformity across the bottle life.
• Preservation or preservative-free microbiological control.
• Extractables and leachables.
• Stability under long-term and in-use conditions.
• Device assembly and supply-chain reliability.

A competitor using the same excipient system may reduce formulation risk but face device equivalence challenges. A competitor changing the preservative or pump may obtain stronger differentiation but incur greater regulatory costs.

What revenue exposure and commercial upside does reformulation create?

Synarel is a niche product rather than a broad primary-care medicine. Revenue exposure is concentrated in two indications and depends on diagnosis rates, specialist prescribing, reimbursement, and generic availability. Public product-level revenue data are not consistently disclosed in current corporate reporting.

The commercial upside from excipient reformulation is therefore more likely to come from margin protection and market retention than from large absolute volume growth. A successful reformulation could:

• Defend the brand against an ANDA entrant.
• Preserve pricing through differentiated labeling.
• Extend use in patients who experience nasal irritation.
• Improve pediatric adherence.
• Support licensing of the device or formulation platform.
• Create a new 505(b)(2) product with separate commercial positioning.

The business case is strongest when the sponsor already owns the brand, manufacturing infrastructure, or device technology. It is weaker for a new entrant that must fund clinical, device, and market-access programs for a small patient population.

What formulation strategy is most commercially attractive?

The preferred strategy is a preservative-free, low-irritation, multidose nasal spray with validated dose uniformity and a caregiver-friendly device. The program should use excipient and device changes together rather than treating them as separate workstreams.

A practical development sequence is:

1. Establish a target pH and osmolality window using nafarelin stability and nasal-tolerability screening.
2. Compare benzalkonium chloride, alternative preservative systems, and preservative-free packaging.
3. Select a multidose pump or unit-dose system based on microbial ingress and dose-uniformity performance.
4. Generate spray-pattern, plume, droplet-size, priming, repriming, and in-use stability data.
5. Build claims around the combined formulation and device architecture.
6. Select ANDA if equivalence is feasible; select 505(b)(2) if meaningful differentiation is required.
7. Position the product around tolerability, pediatric administration, adherence, or preservative avoidance.

Key Takeaways

• Synarel is a nafarelin acetate nasal solution containing benzalkonium chloride, citric acid, sodium chloride, and purified water.
• The main excipient opportunity is replacing benzalkonium chloride through preservative-free multidose or unit-dose delivery.
• Excipient changes alone may be difficult to protect broadly; formulation claims should be linked to stability, tolerability, microbiological control, or dose performance.
• Device patents may provide stronger lifecycle protection than broad nasal-solution claims.
• An ANDA is most suitable for a close generic equivalent. A 505(b)(2) pathway is more suitable for a preservative-free, device-led, or clinically differentiated product.
• Biosimilar competition is irrelevant because Synarel is a small-molecule drug.
• Commercial upside is primarily lifecycle defense, premium positioning, and adherence improvement rather than large-volume market expansion.
• The most defensible product concept is a preservative-free or low-irritation nasal spray with controlled dosing and pediatric-friendly packaging.

FAQs About Synarel Excipients and Commercial Strategy

Is benzalkonium chloride necessary in Synarel?

It is necessary for the labeled multidose product’s preservative strategy, but it is not inherently required for every future nafarelin nasal presentation. A preservative-free product would need a different container-closure and microbiological-control strategy.

Can a company launch a generic Synarel without benzalkonium chloride?

A product that materially changes the excipient system may not qualify as a straightforward ANDA equivalent. It could require a 505(b)(2) application, depending on the extent of the formulation and device changes.

Is nafarelin eligible for biosimilar competition?

No. Nafarelin is a synthetic small-molecule drug. Competition would arise through generic, hybrid, or reformulated drug applications rather than the biosimilar pathway.

What is the most valuable patent claim for a new Synarel product?

A combined claim covering nafarelin concentration, pH, osmolality, preservative status, pump performance, and stability may be more valuable than a broad claim directed only to an excipient substitution.

Could a unit-dose Synarel product command a premium?

Potentially. Unit-dose packaging could eliminate conventional preservatives and improve microbiological control, but the premium would need to offset higher packaging cost, waste, and administration burden.

References

1. U.S. Food and Drug Administration. (n.d.). Synarel (nafarelin acetate) nasal solution prescribing information. Pfizer Laboratories.

2. Bernstein, I. L. (2004). Is the use of benzalkonium chloride as a preservative in nasal formulations a safety concern? Journal of Allergy and Clinical Immunology, 113(1), 176-178.

3. U.S. Food and Drug Administration. (2002). Guidance for industry: Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

5. U.S. Food and Drug Administration. (2002). Guidance for industry: Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. FDA.

6. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.